Clinical Trials
14 trialsNCT05951049 2026-05-06
A Study of AT-02 in Subjects With Systemic Amyloidosis.
Attralus, Inc.
Phase 2 Active not recruiting
NCT07524634 2026-04-24
Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
Case Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT06649695 2026-04-21
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
European Myeloma Network B.V.
Phase 2 Recruiting
NCT05898646 2026-03-30
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Mayo Clinic
Phase 2 Recruiting
NCT07224672 2026-03-17
ALANIS
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT04270175 2026-02-27
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT07335887 2026-01-13
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT03618537 2025-12-04
Ixazomib Maintenance Study in Patients With AL Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT07110844 2025-11-19
Teclistamab-Daratumumab in AL Amyloidosis
Columbia University
Phase 2 Recruiting
NCT03315026 2025-11-04
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03499808 2025-09-09
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
SWOG Cancer Research Network
Phase 2 Completed
NCT04617925 2025-09-05
EMN27
European Myeloma Network B.V.
Phase 2 Completed
NCT07079423 2025-07-23
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT07055724 2025-07-09
Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis
Nanjing IASO Biotechnology Co., Ltd.
Phase 2 Not yet recruiting